Joel Sendek Quotes

While our macro view is bullish on small-cap biotech for 2006, we do not recommend indiscriminate buying. - Joel Sendek

The company came through with about 38% operating margins this quarter, guiding 42% over the next couple of year. That's dramatic translation of top-line revenues to the bottom line. - Joel Sendek

Page 1 of 1